Published on Saturday August 06, 2022

We are working on the following new projects:

  • We were awarded with two contracts for full-service support in bioequivalence trials with Rivaroxaban 10 mg and 20 mg.
  • Smooth signed a contract for a synopsis development with Rabeprazole.
  • A contract for medical writing services was signed with Mebeverine.

We are happy to reach the following milestones in our projects:

  • The clinical part was completed in the Rivaroxaban, 10 mg and Gabapentin trials.
  • The site was initiated in the Rivaroxaban, 20 mg and the Rivaroxaban, 2,5 mg trial.
  • The last site was closed in the Azacitidine trial.